PPD Development, LP
Austin, Texas, 78744, United States
NCT Number: NCT03657030
This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 1
Austin, Texas, 78744, United States
Part 1: Single-Dose Regimen and Fasted-Fed Crossover - For the single-dose regimen, approximately 40 healthy male and female subjects will be enrolled in 1 of 5 single dose cohorts (designated as S1 through S5, respectively) in an ascending fashion.
Part 2: Multiple-Dose Regimen
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SAD / MAD
Placebo
Time frame: Baseline through 14 days post-dose
Occurrence of all adverse events from signing of informed consent through end of study treatment.
Time frame: Baseline through 14 days post-dose
RBC
Time frame: Baseline through 14 days post-dose
Oral Temperature (°C )
Time frame: Baseline through 14 days post-dose
Standard 12-lead ECG - QT interval
Time frame: Baseline through 14 days post-dose
Weight and Height will be combined to calculate BMI using the following formula: BMI = weight (kg)/[height (m)]2
Time frame: Baseline through 14 days post-dose
ALT
Time frame: Baseline through 14 days post-dose
pH
Time frame: Baseline through 14 days post-dose
Respiration rate
Time frame: Baseline through 14 days post-dose
Pulse rate
Time frame: Baseline through 14 days post-dose
Blood pressure (both systolic and diastolic)
Time frame: Baseline through 14 days post-dose
WBC with differential (%and absolute) platelets, PT/INR
Time frame: Baseline through 14 days post-dose
Hemoglobin
Time frame: Baseline through 14 days post-dose
Hematocrit
Time frame: Baseline through 14 days post-dose
PT/INR
Time frame: Baseline through 14 days post-dose
Platelets
Time frame: Baseline through 14 days post-dose
Standard 12-lead ECG- QTcB interval
Time frame: Baseline through 14 days post-dose
Standard 12-lead ECG - QTcF interval
Time frame: Baseline through 14 days post-dose
Standard 12-lead ECG - RR interval
Time frame: Baseline through 14 days post-dose
Standard 12-lead ECG - QRS interval
Time frame: Baseline through 14 days post-dose
Standard 12-lead ECG - PR interval
Time frame: Baseline through 14 days post-dose
Albumin
Time frame: Baseline through 14 days post-dose
Alkaline phosphatase
Time frame: Baseline through 14 days post-dose
Lipase
Time frame: Baseline through 14 days post-dose
AST
Time frame: Baseline through 14 days post-dose
Total bilirubin
Time frame: Baseline through 14 days post-dose
Direct bilirubin
Time frame: Baseline through 14 days post-dose
Total protein
Time frame: Baseline through 14 days post-dose
Creatinine
Time frame: Baseline through 14 days post-dose
Blood urea nitrogen
Time frame: Baseline through 14 days post-dose
Creatine kinase Glucose, Chloride, Bicarbonate
Time frame: Baseline through 14 days post-dose
GGT
Time frame: Baseline through 14 days post-dose
Potassium
Time frame: Baseline through 14 days post-dose
Sodium
Time frame: Baseline through 14 days post-dose
Glucose
Time frame: Baseline through 14 days post-dose
Chloride
Time frame: Baseline through 14 days post-dose
Bicarbonate
Time frame: Baseline through 14 days post-dose
Calcium
Time frame: Baseline through 14 days post-dose
Specific gravity
Time frame: Baseline through 14 days post-dose
Protein
Time frame: Baseline through 14 days post-dose
Glucose
Time frame: Baseline through 14 days post-dose
Blood
Time frame: Baseline through 14 days post-dose
Nitrite
Time frame: Baseline through 14 days post-dose
Microscopic Analysis (only if positive dipstick results): RBC/high power field, WBC/high power field, Epithelial cells, casts
Time frame: SAD: PK Collection on Day 1-4, and early termination (up to 8 days); MAD: PK Collection on Day 1-10, and early termination (up to 14 days)
To evaluate the pharmacokinetics of single and multiple doses of CVN424. Pharmacokinetic parameters including, but not limited to area under the plasma concentration-time curve (AUC) from 0 to 24hours (AUC0-24)
Time frame: SAD: PK Collection on Day 1-4, and early termination (up to 8 days); MAD: PK Collection on Day 1-10, and early termination (up to 14 days)
To evaluate the pharmacokinetics of single and multiple doses of CVN424. Pharmacokinetic parameters including, but not limited to maximum plasma concentration (Cmax).
Time frame: Baseline through 14 days post-dose
Assess the effect of food on the bioavailability in the current formulation after digesting a high caloric meal.
Time frame: Baseline through 14 days post-dose
Assess the effect of food on the bioavailability in the current formulation after digesting a high caloric meal.
Time frame: Day 1
Drug metabolic enzyme and transporter polymorphisms that may contribute to variability in CVN424 will be reported.
Single-dose -pre-dose
Multi-dose
-pre-dose
Time frame: Day 1 and Day 7
Single-dose -pre-dose, 8 and 24 hours post dose
Multi-dose
-pre-dose, 8 and 24 hours post dose
Cerevance Beta, Inc.
Industry
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN424 in Healthy Subjects
Acronym: CVN424
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details